Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798617 | 0.88 | PIK3CG (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL2143788 | 0.85 | LMNA (0.40) | ALDH1A1SMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL14231194 | 0.85 | RAB9A (0.39) | ALDH1A1SMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL3273615 | 0.85 | LMNA (0.39) | ALDH1A1SMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL3272226 | 0.85 | DYRK1A (0.46) | ALDH1A1SMN1; SMN2RAB9APOLBL3MBTL1 | |
| SCHEMBL14365580 | 0.85 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL2143829 | 0.84 | MAPT (0.42) | ALDH1A1SMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL3274675 | 0.84 | KMT2A (0.46) | ALDH1A1SMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL2143844 | 0.84 | RAB9A (0.51) | ALDH1A1SMN1; SMN2NPC1RAB9APOLB | |
| SCHEMBL1117899 | 0.84 | PIK3CG (0.41) | ALDH1A1SMN1; SMN2NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802636-B1 | PI3 KINASES INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-03-27 | — | — | EP | disclosed |
| US-8232286-B2 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232286-B2 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232286-B2 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8207349-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207349-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207349-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| CN-101035795-B | Thiazolyl dihydroindazoles | BOEHRINGER INGELHEIM INT | 2012-03-21 | — | — | CN | disclosed |
| EP-2343303-A1 | PI3-kinase inhibitors | Boehringer Ingelheim International GmbH (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343303-A1 | PI3-kinase inhibitors | Boehringer Ingelheim International GmbH (DE) | 2011-07-13 | — | — | EP | disclosed |
| US-7691888-B2 | Thiazolyl-dihydro-indazole | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20090156554-A1 | P13-KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156554-A1 | P13-KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-1799690-B1 | THIAZOLYL-DIHYDRO INDAZOLES | BOEHRINGER INGELHEIM INT (DE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1799690-B1 | THIAZOLYL-DIHYDRO INDAZOLES | BOEHRINGER INGELHEIM INT (DE) | 2008-04-16 | — | — | EP | disclosed |
| CN-101035795-A | Thiazolyl dihydroindazoles | BOEHRINGER INGELHEIM INT (DE) | 2007-09-12 | — | — | CN | disclosed |
| EP-1799690-A1 | THIAZOLYL-DIHYDRO INDAZOLES | Boehringer Ingelheim International GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
| US-20060106013-A1 | PI3-kinases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-18 | — | — | US | disclosed |
| US-20060100254-A1 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006040281-A1 | THIAZOLYL-DIHYDRO INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100254-A1 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | CDK1, MAPK1, NFATC1 | ALDH1A1 1013/4885SMN1; SMN2 3431/4885NPC1 920/4885 |
| US-20090156554-A1 | P13-KINASES | PIK3C3, PDPK1, MAP3K13 | ALDH1A1 3040/4885SMN1; SMN2 3429/4885NPC1 4417/4885 |
| US-20060106013-A1 | PI3-kinases | PIK3C3, PIK3CB, PIK3CD | ALDH1A1 1935/4885SMN1; SMN2 3272/4885NPC1 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.